A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in New York from January 2017 through December 2017.
Of health plans that received at least 350 claims for PCSK9 inhibitors, the following had the highest rates of rejections:
• Fidelis Care NY – 43%
• United Health Group – 34%
• Express Scripts – 34%
• Independent Health – 25%
The following had the lowest rates of rejection:
• Aetna – 12%
• Humana Health Plan – 9%
